Cyclooxygenase-2 immunohistochemistry in human melanoma: Differences between results obtained with different antibodies

Melanoma Research

Volumn 19, Issue 5, 2009, Pages 294-300

  Kuzbicki, Łukasz ^a   Lange, Dariusz ^b   Chwirot, Barbara W ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cyclooxygenase 2; Human melanoma; Immunohistochemistry

Indexed keywords

ANTIBODY; CYCLOOXYGENASE 2; EPITOPE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KERATINOCYTE; MELANOCYTIC NEVUS; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY;

ANTIBODIES; CYCLOOXYGENASE 2; EPITOPES; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS, PIGMENTED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 73349107766     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832e0bde     Document Type: Article

References (25)

1. Denkert C, Koebel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61:303-308.
2. Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C, Bhattacharyya A, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003; 2:713-718.
3. Sun B, Zang S, Zhao X, Liu Y, Ni C, Zhang D, et al. Correlation of VEGF and COX-2 expression with VM in malignant melanoma. Chinese J Clin Oncol 2004; 1:322-327.
4. Jung DS, Oh CK, Jang HS, Kim MB, Kwon KS. Expression of cyclooxygenase-2 in malignant melanoma. Korean J Dermatol 2005; 43:15-21.
5. Kużbicki Ł, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 2006; 16:29-36.
6. Bianchini F, Massi D, Marconi C, Franchi A, Baroni G, Santucci M, et al. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostaglandins Other Lipid Mediators 2007; 83:320-328.
7. Chwirot BW, Kużbicki Ł. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res 2007; 17:139-145.
8. Johansson CC, Egyhazi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, et al. Prognostic significance of tumour iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother 2008; 58:1085-1094. doi 10.1007/s00262-008-0631-1.
9. Lee C, Ramirez JA, Guitart J, Diaz LK. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. J Cutan Pathol 2008; 35:989-994.
10. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res 2009; 19:8-16.
11. Callejo SA, Caissie AL, Mendez MC, Figueiredo AM, Ozdal PM, Burnier MN. Cyclooxygenase-2 (COX-2) expression in malignant uveal melanoma: its role in disease progression. Invest Ophtalmol Vis Sci 2002; 43: [E-Abstract 1134].
12. Figueiredo A, Caissie AL, Callejo SA, McLean IW, Gold P, Burnier MN. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Can J Ophtalmol 2003; 38:352-356.
13. Frota ACA, Odashiro AN, Pereira PR, Fernandes BJ, Godeiro KD, Filho JPS, et al. Immunohistochemical expression of COX-2 and c-kit in metastatic uveal melanoma. Can J Ophtalmol 2007; 42:145-146.
14. Cryan LM, Paraoran L, Hiscott P, Damato BE, Grierson I, Farrell M, et al. Expression of COX-2 and prognostic outcome in uveal melanoma. Curr Eye Res 2008; 33:177-184.
15. Ozdal PC, Callejo S, Caissie AL, Edelstein C, Bakalian S, Vianna RNG, et al. Cyclooxygenase-2 expression in human irradiated uveal melanomas. Int Ophtalmol 2008; 28:1-6.
16. Wilson KS, Allan SJ. Clinical activity of celecoxib (CXB) in metastatic malignant melanoma (MMM). J Clin Oncol 2005; 23:7555.
17. Lejeune FJ, Monnier Y, Rueg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res 2006; 16:263-265.
18. Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, et al. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the hellenic cooperative oncology group. Annals Oncol 2006; 17:1835-1841.
19. Marshall J-CA, Fernandes BF, Di Cesare S, Maloney S, Logan P, Antecka E, et al. The use of cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis 2007; 28:2053-2058.
20. Kast RE. Melanoma inhibition by cyclooxygenase inhibitors. Med Oncol 2007; 24:1-6.
21. Asgari MM, Maruti SS, White E. A large cohort study of nonsteroidal antiinflammatory drug use and melanoma incidence. J Natl Cancer Inst 2008; 100:1-5.
22. Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, et al. Progression and NASID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001; 11:587-599.
23. Leong J, Hughens-Fulford M, Rakhlin N, Habib A, Maclouf J, Goldyne ME. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res 1996; 224:79-87.
24. Goldyne ME. Cyclooxygenase isoforms in human skin. Prostaglandins Other Lipid Mediat 2000; 63:15-23.
25. De Groot DJA, De Vries EGE, Groen HJM, De Jong S. Non-steroidal antiinflammatory drugs to potentiate chemotherapy effects: From lab to clinic. Critical Rev Oncol/Hematol 2007; 61:52-69.